Physician profile
David S Salm
NPI 1184727273
$2,631.02
in general payments reported to CMS, 2019-2025
29 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,358 · 2024: $18.38 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $232.74 | 2019 | |
| Amgen INC. | $188.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $170.18 | 2019-2024 | Saphnelo |
| Pfizer INC. | $169.41 | 2019-2025 | |
| Lilly USA, LLC | $129.44 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.09 | 2019 | |
| Merck Sharp & Dohme LLC | $119.25 | 2019 | |
| Amarin Pharma, INC. | $118.03 | 2019 | |
| Circassia INC. | $71.82 | 2019 | |
| Shire North American Group INC | $63.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $56.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $53.70 | 2025 | Rexulti |
| Lundbeck LLC | $51.75 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $47.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.91 | 2025 | |
| Glaxosmithkline, LLC. | $44.45 | 2019 | |
| Vanda Pharmaceuticals INC. | $44.41 | 2025 | Fanapt |
| Allergan, INC. | $44.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.22 | 2019 | |
| Vivus LLC | $33.84 | 2019 | |
| Avanir Pharmaceuticals, INC. | $26.38 | 2019 | |
| Baxter Healthcare | $25.90 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Astellas Pharma US INC | $24.09 | 2019 | |
| Exact Sciences Corporation | $22.96 | 2025 | |
| Radius Health, INC. | $19.29 | 2019 | |
| Abbvie INC. | $16.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Salm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.